Company: INMB
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001213900-25-104141
Chunk: 24

Company: Inmune Bio, Inc.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 1
Chunk 24
---
.56 per share under the ATM program. The aggregate net proceeds were approximately $775,000 after
offering expenses. These shares were inadvertently sold under a registration statement filed with the SEC that had in fact expired prior
to the time the shares were sold.   The Company reclassified 75,697 shares, with an aggregate purchase price of $799,000 of
its common stock as temporary equity presented outside stockholders’ equity as a result of potential rescission rights. As
of September 30, 2024, the rescission rights for these shares lapsed and the shares were reclassified to permanent equity.

Stock options

During August 2025, the Company modified stock
option awards held by its former Chief Executive Officer to extend the post-termination exercise period and provide that unvested stock
options shall continue to vest pursuant to the severance agreement, which will result in additional stock-based compensation expense of
up to $2.4 million to be expensed over the remaining original vesting term, if any, of the stock option awards.

The following
table summarizes stock option activity during the nine months ended September 30, 2025:

  (in thousands, except share and per share amounts)  Number of Shares   Weighted- average Exercise Price   Weighted- average Remaining Contractual Term (years)   Aggregate Intrinsic Value   Outstanding at January 1, 2025   7,203,307   $8.29    6.49   $1,218   Options granted   100,000   $7.88    10.0    -   Options exercised   -   $-    -    -   Options cancelled   (107,965)  $7.50    -    -   Outstanding at September 30, 2025   7,195,342   $8.29    5.80   $-   Exercisable at September 30, 2025   5,379,014   $8.80    4.81   $-  

During the three and nine months ended September
30, 2025, the Company recognized stock-based compensation expense of approximately $3.0 million and $6.6 million, respectively, related
to the vesting of stock options. During the three and nine months ended